Advancis Pharmaceutical Corp., of Gaithersburg, Md., appointed Kevin Sly senior vice president, business development and strategy marketing.
Allos Therapeutics Inc., of Westminster, Colo., appointed Josefin-Beate Holz director, clinical development.
Arradial Inc., of Bedford, Mass., appointed Mark Tepper president and CEO and John Havens senior vice president, technology.
Axxima Pharmaceuticals AG, of Martinsried, Germany, named Jürgen Drews chairman of its board, Axel Ullrich vice chairman of the board and Björn Hoffstedt to its board.
BioProcessors Corp., of Woburn, Mass., added Mike Pavia to its scientific advisory board.
Cambrex Corp., of East Rutherford, N.J., appointed Aaron Heifetz vice president, general manager and site director of Cambrex Bio Science Inc.
Carrington Laboratories Inc., of Irving, Texas, appointed Kenneth Yates president of DelSite Biotechnologies Inc., its wholly owned subsidiary.
Cephalon Inc., of West Chester, Pa., appointed Franck Kiser vice president, worldwide drug delivery technologies.
Cerus Corp., of Concord, Calif., appointed William Rohn to its board.
Orchid BioSciences Inc., of Princeton, N.J., appointed Kenneth Noonan to its board.
Rigel Pharmaceuticals Inc., of South San Francisco, added Elliott Grossbard as senior vice president of medical development.
Serologicals Corp., of Atlanta, appointed Joseph Kozma vice president of strategic market development.
Therion Biologics Corp., of Cambridge, Mass., appointed Peter Wolfe and Trudie Resch to its board.